Halozyme Therapeutics (HALO) Raw Materials (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Raw Materials of $21.9 million for Q1 2026, up 18.9% year-over-year from $18.4 million in Q1 2025, and little changed quarter-over-quarter from $21.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Raw Materials (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Raw Materials for 16 consecutive years, with $21.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Raw Materials rose 18.9% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at $21.9 million (up 18.9% YoY), while the FY2025 annual figure was $21.9 million, down 8.94% from the prior year.
- Raw Materials steadied at $21.9 million in Q1 2026 per HALO's latest filing, from $21.9 million in the prior quarter.
- Across five years, Raw Materials topped out at $30.6 million in Q3 2024 and bottomed at $10.2 million in Q2 2022.
- Historically, Raw Materials has averaged $20.8 million across 5 years, with a median of $21.9 million in 2026.
- Annual changes were most pronounced in 2023 — Raw Materials surged 137.5% — and 2025, when it sank 37.99%.
- Halozyme Therapeutics' Raw Materials stood at $13.8 million in 2022, then surged by 71.45% to $23.6 million in 2023, then rose by 1.56% to $24.0 million in 2024, then slipped by 8.94% to $21.9 million in 2025, then increased by 0.15% to $21.9 million in 2026.
- Business Quant data shows HALO's Raw Materials at $21.9 million in Q1 2026, $21.9 million in Q4 2025, and $19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.40 Mn |
| Mar 31, 2026 | 21.90 Mn |
| Dec 31, 2025 | 21.87 Mn |
| Sep 30, 2025 | 18.96 Mn |
| Jun 30, 2025 | 17.79 Mn |
| Mar 31, 2025 | 18.42 Mn |
| Dec 31, 2024 | 24.02 Mn |
| Sep 30, 2024 | 30.58 Mn |
| Jun 30, 2024 | 27.22 Mn |
| Mar 31, 2024 | 29.11 Mn |
| Dec 31, 2023 | 23.65 Mn |
| Sep 30, 2023 | 26.93 Mn |
| Jun 30, 2023 | 24.21 Mn |
| Mar 31, 2023 | 22.45 Mn |
| Dec 31, 2022 | 13.79 Mn |
| Sep 30, 2022 | 11.96 Mn |
| Jun 30, 2022 | 10.19 Mn |
| Mar 31, 2022 | 10.27 Mn |
| Dec 31, 2021 | 10.67 Mn |
| Sep 30, 2021 | 8.11 Mn |